anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
BACKGROUND: Immune regulation by gut microbiota is affected by dysbiosis and may precede food allergy onset. Prior studies lacked comparisons stratified by age and clinical phenotype.
OBJECTIVE: To assess the microbiome of children with food allergy (<3 years, 3-18 years) compared with similar aged children without food allergy.
METHODS: A real-world prospective cross-sectional study performed from 2014 to 2019 recruited children highly likely to have milk, egg, or peanut allergy defined by history and serum IgE or confirmed by food challenge. 16S ribosomal RNA sequencing identified stool microbial DNA. Alpha and beta diversity was compared between groups with food allergy and healthy controls stratified by age. Differential abundance for non a priori taxa was accepted at absolute fold-change greater than 2 and q value less than 0.05.
RESULTS: A total of 70 patients were included (56 with food allergy and 14 healthy controls). Groups were not significantly different in age, gender at birth, race, mode of delivery, breastfeeding duration, or antibiotic exposure. Younger children with food allergy had similar alpha diversity compared with controls. Beta diversity was significantly different by age (P = .001). There was differential abundance of several a priori (P < .05) taxa (including Clostridia) only in younger children. Both a priori (including Coprococcus and Clostridia) and non a priori (q < 0.05) Acidobacteria_Gp15, Aestuariispira, Tindallia, and Desulfitispora were significant in older children with food allergy, especially with peanut allergy.
CONCLUSION: Dysbiosis associates with food allergy, most prominent in older children with peanut allergy. Younger children with and without food allergy have fewer differences in gut microbiota. This correlates with clinical observations of persistence of peanut allergy and improved efficacy and safety of oral immunotherapy in younger children. Age younger than 3 years should be considered when initiating therapeutic interventions.
Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
Chronic urticaria (CU) is one of the most common dermatological diseases and has a significant impact on the quality of life of patients. However, the pathogenesis of this disease remains unclear. Autoimmunity in chronic spontaneous urticaria (CSU) has received considerable attention and has been studied previously. Atopy is an important characteristic of CU; however, it has not been fully recognized. Atopy predisposes individuals to immune responses to allergens, leading to type 2 inflammation and immunoglobulin E (IgE) overproduction. Compared with healthy individuals, patients with CU have a higher proportion of atopy, and an atopic background is correlated with the clinical characteristics of CU. The total IgE levels in patients with CU is significantly higher than those in healthy individuals. Although its level is not higher than that in classic allergic diseases, it is closely related to CU. Exogenous allergens, auto-allergens, and specific IgEs, which are closely related to atopy, have been reported, and their roles in CU pathogenesis are also being studied. Local and systemic atopic inflammation is present in patients with CU. This review summarizes the current knowledge regarding atopy and CU, speculating that there are CU subtypes, such as atopic CSU or atopic chronic inducible urticaria (CIndU) and that atopy may be involved in the pathogenesis of CU. These findings provide a new perspective for a comprehensive understanding of the clinical features of CU and further research regarding its pathogenesis.
Prospective data base of 100 consecutive morbidly obese patients who had undergone transit bipartition (TB, also termed "Single Anastomosis Sleeve Ileal bypass") after a previous sleeve gastrectomy (LSG). Inclusion criteria were TB for excess weight loss (EWL) \< 50% ≥ 12 months post LSG or weight recidivism of \> 5 kg/qm with a body mass index (BMI) \> 30 kg/qm. Patients with endocrine disorders other than type 2 diabetes mellitus (T2D), major psychiatric disorders, American Society of Anesthesiologists (ASA) III and higher or pregnant patients were excluded from the study. Data were prospectively collected in strictly pseudonymous form. Follow up time points were at 1, 3, 6 and 12 months following TB. The primary endpoint of the study is weight loss at 1, 3, 6 and 12 months after TB. A subgroup analysis evaluates the effect of the length of the common channel. Secondary endpoints include impact on obesity related comorbidities such as T2D, hypertension, sleep apnea, gastroesophageal reflux as well as safety.
Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker \& Klion) - weekly for a period of 12 months. No control/comparison group.
Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
AIM: The primary aim was to compare the body awareness (BA) level in adults with obesity and non-obese adults. The secondary aim was to investigate the physical parameters associated with BA and compare them between adults with obesity and non-obese adults.
METHOD: Thirty-two adults with obesity and age and sex-matched 32 non-obese adults were included in the study. The outcome measures were the Body Awareness Questionnaire, International Physical Activity Questionnaire-Short Form and Functional Reach Test to detect BA, physical activity (PA), and dynamic balance level, respectively. Reaction time was assessed by the Nelson Foot Reaction Test and knee and trunk position error by inclinometer.
RESULTS: There was no significant difference between the obese and non-obese group in terms of BA score (p = 0.18) and PA level (p = 0.50). Lower dynamic balance was observed in the obese group (p = 0.003). Only the trunk position error was higher in the obese group in the measurement of joint position error (p = 0.010). There were no significant differences in the right and left feet reaction times between the groups (p = 0.68 and p = 0.23). There were no relationships between BA score and PA level (p = 0.93), dynamic balance (p = 0.82), joint position error (p = 0.14), and right (p = 0.33) and left (p = 0.25) reaction times.
CONCLUSION: There was no significant difference in body awareness between the non-obese and the obese group and there was no association between body awareness and the physical parameters. However, adults with obesity had impaired balance and proprioception compared to non-obese ones.
Sleep disorders are prevalent among the general population and even more in individuals suffering from chronic diseases. Recent data reveal promising effects of physical exercise as a non-pharmacological approach for improving sleep and managing various sleep disorders. However, more studies with proper design and methodology should be conducted in the future to obtain a clearer understanding of the subject. The role of exercise in preventing and improving sleep disorders is probably much higher than what is currently exploited. To fully exploit the potential benefit of physical activity on sleep disorders in the future, it is necessary to identify the relevant tools to assess sleep-wake disorders and establish specific exercise protocols tailored to different sleep disorders. The present manuscript aims to review the literature on the use of exercise in managing selected sleep disorders. Regular exercise, including short-term aerobic activity, resistance training, and mind-body exercises, can effectively improve sleep quality, particularly in cases of insomnia and sleep-disordered breathing. Additionally, increasing evidence supports the effectiveness of aerobic and strength training, and body-mind exercises such as yoga in managing sleep-related movement disorders. Exercise can be a safe, affordable, and efficient tool in enhancing sleep quality and improving sleep disorders. Per se, regular exercise could play an adjuvant role alongside with established therapies, or a valid alternative when the pharmacological approach is limited by side effects, interactions, or inefficacy. More research is needed to define how exercise affects the physiology of sleep, and consequently how to use exercise in patients with sleep disorders.
PURPOSE:A slightly releasable sealant having improved permeability, consisting of a polymerizable monomer containing bisphenol A diglycidyl dimethacrylate, a hydrophilic monomer and a hydrophobic monomer and a curing agent containing a peroxide catalyst and a promotor. CONSTITUTION:The titled composition consisting of a polymerizable monomer comprising 30-60pts.wt. bisphenol A diglycidyl dimethacrylate, 5-20pts.wt. bisphenol A di(polyethoxyethyl) dimethacrylate as a hydrophobic monomer, 15- 40pts.wt. 2-hydroxyethyl methacrylate as a hydrophilic monomer, and, additionally, 0-20pts.wt. neopentyl glycol dimethacrylate and 0-20pts.wt. triethylene glycol dimethacrylate, and a curing agent comprising a peroxide catalyst (e.g., benzoyl peroxide) and a promotor. Wetting of the teeth is improved by the hydophilic monomer, water resistance is maintained by the hydrophobic monomer, and maintenance ratio of scissura of suleus of the teeth can be raised.
Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
Body mass index (BMI) is routinely used to ascertain health status, including activities of daily living (ADLs); however, the associations of ADLs with height and weight in older adults have not been elucidated. Therefore, we cross-sectionally investigated the correlations between ADLs and height, weight, and BMI in 155 participants aged 82 to 103 years and characterized the naïve Bayesian prediction for ADLs. Activities of daily living showed a significant negative correlation with height and weight and a positive correlation with age. In males, a shorter height was associated with an increased risk of falling and disability in phone calling independently, and losing weight was associated with an increased risk of disability in going out. Combining age, weight, and height improved the area under the receiver operating characteristic curve in the prediction of disability in going out and phone calling independently in males. Therefore, height and weight, not BMI, are potential predictors of ADL decline.
Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1346891 Alkaloids T WANDJI 18 Jan 1973 2702/73 Heading A5B An alkaloid Difeuine I, Difeuine II or Difeuine III and mixtures thereof are obtained by extracting the root of Pentadiplandra brazzeana (known in the Nde district of Cameroon as "Difeu") with alcohol, preferably 95% by volume ethyl alcohol, and evaporating the alcohol from the resulting solution in the absence of air under reduced pressure at a temperature of about 40‹C. Difeuine I has a lemon yellow colour, precipitates with the general reagents used for alkaloids, the evaporation residue from an alcoholic solution shows a violet colouration when treated with 10% by weight potassium hydroxide and Lafon's reagent, and in a solvent system comprising benzene, acetone and ammonia (100 ml, 20 ml, 20 ml) it forms spots of Rf 0.10 to 0.30, Difeuine II has a blackish brown colour due to oxidation by oxygen occurring the atmosphere, precipitates with the general reagents used for alkaloids, an alcoholic solution assumes a violet colouration when treated with concentrated nitric or sulphuric acid, an evaporation residue assumes a violet colouration when treated with Lafon's reagent, contains C 65.27%, H 7.26%, N 5.29% and O 14.4%, in a solvent system comprising benzene, acetone and ammonia (100 ml., 20 ml., 20 ml.), it forms spots of Ff 0.47-0.60, and a UV absorption spectrum in 95% alcohol shows maxima at 270, 220 and 200 nm; and Difeuine III has a dull brown colour due to oxidation by oxygen occurring in the atmosphere, precipitates with the general reagents used for alkaloids, contains C 54.31%, H 5.79%, N 3.10%, S 3.62% and O 29%, an alcoholic solution assumes a violet colouration when treated with concentrated nitric or sulphuric acid, an evaporation residue assumes a violet colouration when treated with Lafon's reagent, in a solvent system comprising benzene, acetone and ammonia (100 ml., 20 ml., 20 ml.) it forms spots of Rf 0.70-0.90 and a UV absorption spectrum shows maxima at 270 and 200 nm. Difeuine I is isolated from the alkaloid mixture by extracting the mixture with ether, e.g. petroleum or diethyl ether, separating the ethereal phase and evaporating the ether from the phase to yield solid Difeuine I, which may be purified by precipitation from an alcoholic solution thereof at 5-6‹C under an inert atmosphere; and Difeuine II and III are isolated by dissolving the non-ethereal phase in chloroform, adding an aqueous alkaline solution, e.g. sodium hydroxide solution, to the resulting solution, separating the aqueous and chloroform phases, evaporating the chloroform from the chloroform phase to yield solid Difeuine II and neutralising the aqueous phase with dilute mineral acid, e.g. hydrochloric acid, and separating the resulting precipitated Difeuine III. Pharmaceutical compositions for use in the treatment of anorexia, haemorrhoids, diarrhoea, amoebiasis, vomiting, colitis, ankylostomiasis, gastroenteritis, water retention conditions and deficiency and other oedemas comprise at least one of the alkaloids Difeuine I, II and III and an inert physiologically acceptable carrier. The compositions may be administered orally or rectally in the form of a solution or syrup.
We propose to study the efficacy of "Ecosystem Focused Therapy" (EFT) in post-stroke depression (PSD), a disorder that afflicts a large number of stroke victims and increases mortality, cognitive impairment, and disability for years after stroke. EFT is a new, home-delivered intervention based on our integrative model of PSD, which originated from our clinical biology and treatment studies in late-life depression. It postulates two main paths to PSD. First, stroke and stroke-repair mechanisms contribute to metabolic changes mediating PSD. Second, a "psychosocial storm" stemming both from the patient's sudden disability and the change in the patient's needs and family life add a biological burden to this cascade of depressogenic events. EFT targets the "psychosocial storm" of PSD and focuses on the reciprocal interaction between the patient's abilities and the challenges of his/her "ecosystem" (family, specialized therapists). EFT follows a structured personalization approach based on the "model of adaptive functioning", in which behavior is a function of the person's competence and the demands of the environment. Thus, EFT continuously "calibrates the environment" to the PSD patient's competence level and targets the PSD "psychosocial storm" through five integrated components: 1) It offers an action-oriented, "new perspective" about the patient's recovery. 2) It provides an "adherence enhancement structure". 3) It offers a "problem solving structure" to the patient focusing on problems, valued by the patient, and pertinent to daily function. 4) It helps the family "reengineer its goals, involvement, and plans" to accommodate the patient's disability. 5) It "coordinates care with specialized therapists" with the goal to increase patient participation in rehabilitation and social activities.
The invention relates to the use of extramembrane proteins in the serological diagnostics of yersiniosis in humans and animals. The extramemberane (secretory) proteins are specific antigens finding application in ELISA and the immunobloth tests by increasing their sensitivity and specificity. They can find application in the medical and veterinary practice. They are secreted from the bacteria in the nutritive media and are precipitated by trichloracetic acid. They are separated by means of electrophoresis in 12% polyacrylamide gels. By them are characterized the yersiniosis antibodies in blood sera and other body liquids of patients and humans and animals which have pulled through the disease.
Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
Pharmaceutically useful trace elements contained in human urine are collected by disposing a filter body containing an adsorbent for the trace elements in the gravity flow line connecting the unflushed urinal of a portable toilet to its holding tank. The portable toilet also includes a seat connected to the holding tank by a separate gravity feed line. The holding tank contains an odor reducing chemical solution for the urine and fesces. A filter body supported in the conduit between the urinal and the holding tank consists of an adsorbent for the trace constituents of the urine that it is desired to extract. Urine voided into the urinal passes through the adsorbent filter body before going to the holding tank. When the holding tank of the portable toilet is pumped clean and the deoderizing solution replaced, the filter body is removed and processed to extract the trace constituents replaced with an unsaturated filter body.
The invention discloses a preparation method of a biomembrane modified ferriferrous oxide nanoparticle. The preparation method comprises the following steps: (1) preparing Fe3O4 water-soluble nanoparticles; (2) preparing Fe3O4 oil-soluble nanoparticles, and reacting a Fe3O4 nanoparticle dry powder with a hexane solution containing silane; and (3) ) preparing Fe3O4 water-soluble nanoparticles by reacting the obtained oil-soluble nanoparticles with a phosphatide vesicle solution. The oil-soluble magnetic nanoparticles can dissolve in an organic carrier to form magnetofluid and can be widely applied. The modified water-soluble nanoparticles have significantly improved stability, and good biocompatibility. The modified oil-soluble magnetic nanoparticles react with the phosphatide vesicle solution to convert into water-soluble nanoparticles; and the reaction has mild conditions and is simple and practicable. The modified phosphatide can solve the problem of biocompatibility, and due to the protection of double molecular films on the surface, the stability of the nanoparticles is substantially enhanced.
OBJECTIVE: The purpose of this study was to investigate the predictive value of mean platelet volume (MPV) and platelet count (PC) in branch atheromatous disease (BAD).
METHODS: This retrospective study included 216 patients with BAD-stroke within 48 h of symptom onset. These patients were divided into good and poor prognosis groups according to their 3-month modified Rankin scale scores after discharge. Multiple logistic regression analysis was used to evaluate independent predictors of poor prognosis in BAD-stroke patients. Receiver-operating characteristic (ROC) analysis was used to estimate the predictive value of MPV and PC on BAD-stroke.
RESULTS: Our research showed that a higher MPV (aOR, 2.926; 95% CI, 2.040-4.196; p < .001) and PC (aOR, 1.013; 95% CI, 1.005-1.020; p = .001) were independently associated with poor prognosis after adjustment for confounders. The ROC analysis of MPV for predicting poor prognosis showed that the sensitivity and specificity were 74% and 84.9%, respectively, and that the AUC was .843 (95% CI, .776-.909, p < .001). The optimal cut-off value was 12.35. The incidence of early neurological deterioration (END) was 24.5% (53 of 163), and 66% of patients in the poor prognosis group had END (33 of 50). Multiple logistic regression analyses showed that elevated MPV and PC were associated with the occurrence of END (p < .05).
CONCLUSION: Our results suggested that an elevated MPV and PC may be important in predicting a worse outcome in BAD-stroke patients. Our study also demonstrated an independent association of MPV and PC with END, which is presumably the main reason for the poor prognosis.
VEXAS syndrome is a recently described entity characterized by systemic inflammatory and hematologic manifestations. The disease was first characterized by Beck et al. in 2020 in a study characterizing 25 patients with undiagnosed adult-onset inflammatory syndromes. While the literature regarding VEXAS syndrome has grown exponentially since 2020, there is still much to be understood. This lack of information leads to challenges in both the diagnosis and treatment of patients with VEXAS syndrome. Patients will often have a variety of clinical symptoms that can lead to missed or delayed diagnoses. Additionally, awareness of VEXAS syndrome is still developing among clinicians. In this comprehensive review, we summarize the current literature regarding VEXAS syndrome, and explore clinical updates of this emerging disease state. Our aim of this review is to increase awareness regarding this new disease state and identify research areas to better understand future treatment approaches for patients with VEXAS syndrome.
Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.